Mubadala Investment is partnering with the La Jolla, California-based National Resilience to establish a new biopharmaceutical manufacturing facility in Abu Dhabi, which will help treat conditions such as cancer, infectious diseases, and inflammatory and autoimmune disorders.
Resilience will operate and manufacture biopharmaceutical-related products from the facility, which will be the first Goods Manufacturing Practice (GMP) biopharma facility in the UAE as well as the first of its kind in the region to manufacture essential life sciences products for advanced biologics.
Read More on the Topic:
- Abu Dhabi: AstraZeneca and G42 Healthcare to set up pharma manufacturing unit
- Abu Dhabi: A global destination for healthcare investment
- Mubadala Health and Mumtalakat to establish long-term facility care in Bahrain
Mubadala is at the forefront of the UAE’s healthcare industry and is advancing the development of the country’s life sciences sector, to build national capabilities and increase national drug security. Over the past two years, it has invested in multiple rounds of equity financing in Resilience.
The agreement with Resilience builds on Mubadala’s decade of world-class patient care and its breakthrough health and wellness solutions. It follows the recent announcement of Mubadala Health and G42 Healthcare joining forces into an integrated healthcare technology company poised to deliver a new approach to personalised, patient-centric care.
Badr Al-Olama, Executive Director, UAE Clusters at Mubadala, and Rahul Singhvi, ScD, Chief Executive Officer of Resilience, signed the agreement in the presence of Musabbeh Al-Kaabi, Chief Executive Officer of UAE Investments at Mubadala.
Al-Olama commented: “We are actively investing in innovation and firmly believe that by strengthening Abu Dhabi’s national life sciences ecosystem, we are building a future-focused, sustainable and knowledge-based economy for the UAE.
“Through this agreement, Mubadala and its group companies will unlock further opportunities for growth within the life sciences ecosystem, and will play an instrumental role in establishing a state-of-the-art biopharma campus that will secure the region’s supply chain from Abu Dhabi.”
Founded in 2020, Resilience is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. It will provide manufacturing, technology and operational expertise to the Abu Dhabi facility, and integrate it as a node within its global network of facilities.
Singhvi added: “We are excited to expand the footprint of our Resilience manufacturing network outside of North America. This is a significant milestone, not just for our company, but also for our nation. We look forward to working alongside America’s allies to ensure that trusted, cutting-edge biopharmaceutical manufacturing capacity is available to support local and regional economies.”
In the wake of the global Covid-19 pandemic, the life sciences sector has become one of the fastest-growing sectors globally, and a priority investment area for private equity and venture capital. The global life science products market is estimated to account for around $5 billion in terms of value by the end of 2027.
Follow us on
